Tumor Mutational Burden Testing in Solid Tumors

Regina Kwon; Heather H Cheng; Colin C Pritchard

doi:10.1001/jamaoncol.2023.4293

Tumor Mutational Burden Testing in Solid Tumors

JAMA Oncol. 2023 Dec 1;9(12):1725-1726. doi: 10.1001/jamaoncol.2023.4293.

Authors

Regina Kwon¹, Heather H Cheng^{2

3}, Colin C Pritchard^{1

4

5}

Affiliations

¹ Department of Laboratory Medicine & Pathology, University of Washington, Seattle.
² Division of Medical Oncology, Department of Medicine, University of Washington, Seattle.
³ Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington.
⁴ VA Puget Sound Health Care System, Seattle, Washington.
⁵ Brotman Baty Institute for Precision Medicine, Seattle, Washington.

PMID: 37883072
DOI: 10.1001/jamaoncol.2023.4293

No abstract available

Plain language summary

A 58-year-old man with diabetes, chronic kidney disease, and JAK2-positive myeloproliferative neoplasm is referred for newly diagnosed oligometastatic prostate cancer with substantial urinary symptoms. What would you do next?

MeSH terms

DNA Mutational Analysis
Humans
Janus Kinase 2 / genetics
Mutation
Myeloproliferative Disorders*
Neoplasms* / genetics

Substances

Janus Kinase 2